January 3, 2011 — Ritedose is voluntarily recalling 0.083% albuterol sulfate inhalation solution in 3-mL single-use dose vials because some vials are embossed with incorrect concentration information, ...

COLUMBIA, S.C., May 20, 2025 /PRNewswire/ -- Ritedose Pharmaceuticals, a division of The Ritedose Corporation (Ritedose), the largest sterile contract development manufacturing organization (CDMO) in ...

Orlando, Florida-based Nephron Pharmaceuticals Corp (NPC) has initiated a voluntary recall at the retail level of 10 lots of albuterol sulfate inhalation solution, 0.083%. The recall affects albuterol ...

Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...

The affected lots are as follows: Lot# A3A33A, A3A33B, A3A34A, A3A35A, A3A36A, A3A37A, A3A38A, A3A40A, A3A41A, and A3A42A. All of the affected lots had passed Nephron’s quality specifications at the ...

The Food and Drug Administration has advised consumers not to use certain respiratory medications purchased after Sept. 8, 2009 and manufactured by Dey L.P., a subsidiary of Mylan Inc., because the ...

Fri, 18 Sep 2009 12:51:42 GMT — The FDA Warns Consumers Not to Use Stolen Albuterol Sulfate Inhalation Solution and Ipratropium Bromide Inhalation Solution. The U.S. Food and Drug Administration today ...

Albuterol (as sulfate) 0.5%. By nebulizer: 2.5mg (0.5mL of 0.5% diluted to 3mL with sterile normal saline, or 3mL of 0.083%) 3–4 times daily. Avoid excessive use. Sensitivity to sympathomimetics.

Ritedose Pharmaceuticals has received the Food and Drug Administration’s approval for manufacturing and distributing generic albuterol sulfate inhalation solution, 0.5% (2.5 mg/0.5 ml). "Driven by the ...

There is a scarcity of a certain albuterol medication product – and the Food and Drug Administration (FDA) said Wednesday night that it is "working to address" that. According to the FDA, the shortage ...

The sudden closure last week of a Gurnee-based pharmaceutical company may prolong shortages of treatments for RSV and asthma. Akorn, which operated manufacturing plants in Decatur, New York and New ...